Recommendations by the Asian Pacific society of nephrology ( APSN ) on the appropriate use of HIF‐PH inhibitors-Reference-Cited by-同舟云学术

Recommendations by the Asian Pacific society of nephrology ( APSN ) on the appropriate use of HIF‐PH inhibitors

Published:2020-12-09 Issue:2 Volume:26 Page:105-118
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Yap Desmond Y. H.¹^ORCID,McMahon Lawrence P.²,Hao Chuan‐Ming³,Hu Nan⁴,Okada Hirokazu⁵,Suzuki Yusuke⁶,Kim Sung Gyun⁷,Lim Soo Kun⁸^ORCID,Vareesangthip Kriengsak⁹,Hung Chi‐Chih¹⁰,Nangaku Masaomi¹¹,

Affiliation:

1. Division of Nephrology, Department of Medicine Queen Mary Hospital, The University of Hong Kong Pok Fu Lam Hong Kong

2. Department of Renal and Obstetric Medicine, Eastern Health Clinical School Monash University Melbourne Australia

3. Divison of Nephrology Huashan Hospital, Fudan University Shanghai P. R. China

4. Renal Division, Department of Medicine Peking University First Hospital, Institute of Nephrology, Peking University Beijing P. R. China

5. Department of Nephrology Saitama Medical University Irumagun Saitama Japan

6. Department of Nephrology Juntendo University Faculty of Medicine Tokyo Japan

7. Department of Internal Medicine Hallym University Sacred Heart Hospital Seoul South Korea

8. Division of Nephrology, Department of Medicine University Malaya Medical Centre Kuala Lumpur Malaysia

9. Division of Nephrology, Department of Medicine Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand

10. Division of Nephrology, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan

11. Division of Nephrology and Endocrinology The University of Tokyo Graduate School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nep.13835

Reference96 articles.

1. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease

2. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease

3. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease

4. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease

5. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia;Clinical Pharmacokinetics;2024-09-11

2. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease;Biomedicines;2024-08-18

3. A spotlight on using HIF-PH inhibitors in renal anemia;Expert Opinion on Pharmacotherapy;2024-07-02

4. Comparative Analysis of Real-World Efficacy and Safety of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Kidney Transplant Recipients Versus Nontransplant Individuals: A Single-Center Study;Transplantation Proceedings;2024-07

5. Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling;Patient Preference and Adherence;2024-07